Jalid Sehouli
Jalid Sehouli is an expert in Oncology at Charité - University Medicine Berlin (Germany). As of October 2026, ScienceLeadR ranks Jalid Sehouli in the top 1% of experts worldwide for Ovarian Neoplasms, Adnexal Diseases and Endocrine Gland Neoplasms. Jalid Sehouli has authored 1,370 publications, the most recent in 2026, and is an investigator in 67 clinical trials, 7 of them ongoing. SLR score: 5,087 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gynecology - Obstetrics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
- Top Urogenital Neoplasms key opinion leaders — ranked #16
Short Biography
Jalid Sehouli is Professor of Gynecology and Gynecologic Oncology at Charité – Universitätsmedizin Berlin and one of Europe’s leading experts in the treatment of gynecologic malignancies. He is President of the PanArabian Research Society of Gynecologic Oncology (PARSGO) and serves in multiple leadership roles within international oncology networks. From 2026, he will assume the presidency of the European Society of Gynaecological Oncology (ESGO). He is the founder of the North-Eastern German Society for Gynecological Oncoogy (NOGGO) and the founder of the German Ovarian Cancer Foundation.
His clinical and scientific focus includes ovarian, endometrial and cervical cancer, rare gynecologic tumors, long-term survivorship, patient-centered care, and communication in medicine. He has authored and co-authored more than 1,000 scientific publications and has led numerous national and international clinical trials.
Beyond his medical career, Jalid Sehouli is an award-winning writer and essayist whose work explores themes of identity, migration, trauma, and healing at the intersection of medicine and literature. His book The Art of Breaking Bad News is regarded as a standard reference in medical communication.
Organizations
Career arc: 1995 - 2026
Number : 1370
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 67
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 5
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Exercise and Nutrition Intervention in Ovarian Cancer NCT06250686 — exercise, muscular atrophy, physical therapists, muscles, atrophy, malnutrition, protein-energy malnutrition, ovary, neoplasms, academic medical centers, recycling, drug therapy, fatigue, ovarian neoplasms, counseling, walk test, universities, carcinoma, ovarian epithelial, chemotherapy, carcinoma | N/A | Recruiting | 2024 |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild Type Advanced or Recurrent Endometrial Carcinoma NCT05611931 — administration, oral, neoplasms, dosage forms, tablets, maintenance, response evaluation criteria in solid tumors, therapeutics, endometrial neoplasms, carcinoma | Phase 3 | Active not recruiting | 2023 |
| A Phase II Randomized Open Label Non inferiority Study of NiraParib Maintenance After 3 vs 6 Cycles of Platinum based Chemotherapy in completeLy debUlked Advanced HRDpositive High grade Ovarian Cancer patientS in First Line Therapy NCT05460000 — cells, adenocarcinoma, clear cell, paclitaxel, fallopian tube neoplasms, ovary, neoplasms, adenocarcinoma, drug therapy, maintenance, ovarian neoplasms, therapeutics, carboplatin, fallopian tubes, chemotherapy, carcinoma | Phase 2 | Recruiting | 2024 |
| Pembrolizumab Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum resistant Recurrent Ovarian Cancer (MK 3475 B96 KEYNOTE B96 ENGOT ov65) NCT05116189 — cells, b7-h1 antigen, lewy bodies, saline solution, parkinson disease, docetaxel, paclitaxel, fallopian tube neoplasms, ovary, neoplasms, bevacizumab, double-blind method, respect, solutions, ovarian neoplasms, response evaluation criteria in solid tumors, therapeutics, ligands, cell death, carcinoma, ovarian epithelial, fallopian tubes, carcinoma | Phase 3 | Active not recruiting | 2021 |
| Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum Taxane based Chemotherapy in Advanced Ovarian Cancer NCT05009082 — area under curve, paclitaxel, fallopian tube neoplasms, ovary, neoplasms, bevacizumab, drug therapy, capsules, ovarian neoplasms, peritoneal neoplasms, carboplatin, carcinoma, ovarian epithelial, fallopian tubes, chemotherapy | Phase 3 | Recruiting | 2022 |
LeadR Networks
Main global connection map